A series of novel ω-substituted alkylthioimidazo[1, 2-b]pyridazines was designed and synthesized in an effort to find a novel anti-asthmatic agent. The anti-asthmatic activity of these compounds was evaluated ont he basis of their ability to inhibit thromboxane A2 synthetase and platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. None of these compounds significantly inhibited thromboxane A2 synthetase, though, sulfonamide derivatives potently inhibited PAF-induced bronchoconstriction. Among them, 3-(imidazo[1, 2-b]pyridazin-6-yl)thiopropanesulfonamide (5) showed the most potent inhibitory effect. The anti-asthmatic effects of compound 5 in experimental models were superior to those of theophylline.
为了找到一种新型抗哮喘药物,我们设计并合成了一系列新型ω-取代烷基
硫代
咪唑并[1,2-b]
哒嗪。根据这些化合物抑制血栓素 A2 合成酶和血小板活化因子(PAF)诱导的豚鼠支气管收缩的能力,对它们的抗哮喘活性进行了评估。这些化合物都不能明显抑制血栓素 A2 合成酶,但磺酰胺衍
生物能有效抑制 PAF 诱导的支气管收缩。其中,3-(
咪唑并[1, 2-b]
哒嗪-6-基)
硫代丙磺酰胺(5)的抑制作用最强。化合物 5 在实验模型中的抗哮喘效果优于茶碱。